

# ForPatients

by Roche

Cervical Cancer

## A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Topotecan in Participants With Advanced Cervical Cancer

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03071848 ML39360

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the safety of bevacizumab (Avastin®) combined with standard chemotherapy in participant with advanced cervical cancer, with special focus on the incidence of gastrointestinal (GI) and genitourinary (GU) fistulas and GI perforations in the common practice setting.

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT03071848 ML39360**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
Female

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---